Nobel Biocare Holding AG holds 94.6 per cent of Nobel Biocare AB and completes the public offer
Nobel Biocare Holding AG holds 94.6 per cent of Nobel Biocare AB and
completes the public offer
The public offer by Nobel Biocare Holding AG to acquire all the
outstanding shares in Nobel Biocare AB has been accepted to such an
extent that Nobel Biocare Holding AG now controls approximately 94.6 per
cent of the shares and votes in Nobel Biocare AB.
All the conditions for Nobel Biocare Holding AG's public offer as stated
in the offer document dated 27 May 2002 have therefore been met and
Nobel Biocare Holding AG will subsequently complete the public offer.
Settlement for those who have accepted the offer up to and including 18
June 2002 will commence on 21 June 2002. Trading of the new shares in
Nobel Biocare Holding AG on the SWX Swiss Exchange and on the Stockholm
Stock Exchange will commence on 24 June 2002.
In order to provide the remaining shareholders of Nobel Biocare AB who
have not tendered their shares during the acceptance period up until 18
June 2002 a further opportunity to tender their shares, Nobel Biocare
Holding AG has decided to extend the acceptance period for these
shareholders up to and including 9 July 2002. Settlement for those
shareholders who will tender their shares during the extended acceptance
period up to and including 9 July 2002 is expected to commence on 12
Nobel Biocare Holding AG intends to request that the board of Nobel
Biocare AB initiates a delisting of Nobel Biocare AB's shares from the
Stockholm Stock Exchange (Stockholmsbörsen) as soon as possible after 9
Gothenburg, 20 June 2002
Nobel Biocare Holding AG
For further information:
Harrieth Sundaeus, Chief Financial Officer, Nobel Biocare AB, tel. +46
31 81 88 48,
mobile +46 708 81 88 48
Michaela Ahlberg, Legal Counsel, Nobel Biocare AB, tel. +46 31 81 88 29,
mobile +46 31 81 88 29.
Copies of this press release are not being, and must not be,
mailed or otherwise distributed or sent in or into Australia or
Japan. The Offer will and is not to be made in these countries.
Statements made in this press release that relate to future
events, performance or financial results of Nobel Biocare are
forward-looking statements which involve uncertainties that
could cause actual events, performance or results to materially
differ. Nobel Biocare undertakes no obligation to update any of
these statements. Readers are cautioned not to place undue
reliance on these forward-looking statements, which speak only
as to the date hereof. Accordingly, any forward-looking
statement should be read in conjunction with the additional
information about risks and uncertainties set forth in Nobel
Biocare's annual reports and in the Offer Document dated 27 May
Nobel Biocare is an innovative, medical devices company, whose core
business comprises dental implants and dental prosthetics. The company's
product systems for dental implants, Brånemark System® and Replace(TM),
are world leaders and have a global market share of around 38%.
The company's other product line, Procera®, is a unique, IT-based
process for the industrial production of dental prosthetics. The system
has been launched very successfully in more than 35 countries in North
America, Europe, South East Asia and South America.
Nobel Biocare has around 1,300 employees and, in 2001 net sales totaled
SEK 2 663 million. The company's headquarters are located in Gothenburg,
Sweden, while production takes place in Sweden and the USA. Nobel
Biocare has its own sales companies in 26 countries.
Nobel Biocare AB, Box 5190, S-402 26 Göteborg, Sweden,
tel +46 31-81 88 00, fax +46 31-16 31 52.